SCBIO

  • Sam Patrick posted an article
    NEW LIFE SCIENCES DISTRICT KICKS OFF CONSTRUCTION IN CHARLESTON, SC AT WESTEDGE see more

    Charleston, SC - July 17, 2018 marked the construction kickoff for 22 WestEdge, a striking new workplace anchor for the city’s growing knowledge economy and the highly anticipated centerpiece of the WestEdge District. The iconic 125-foot, eight-story structure will be the tallest multi-tenant office building on the peninsula and in Charleston’s metropolitan area when it opens in November 2019.

    “22 WestEdge affirms the vision for a Live, Learn and Earn district, adding vital office, research and lab components to the world class WestEdge community. It builds on the remarkable momentum of a development that already has over $300 million under construction,” said Michael Maher, CEO of The WestEdge Foundation, Inc., the non-profit sponsor of the overall development.

    Even prior to the 22 WestEdge groundbreaking, area economic development proponents including The Medical University of South Carolina, the South Carolina Research Authority, the City of Charleston, Heritage Trust and the WestEdge Foundation committed to 22 WestEdge, forming the nucleus of entities working to incubate, attract and retain entrepreneurial talent to energize the Charleston economy.  While 48% of the space is currently leased, 72,000 square feet of office space and 10,000 square feet of retail space remain available for existing local businesses, or for new companies being created or relocating to the Charleston region. This is a remarkable concentration of ingenuity¾over 35,000 people live, work, study and seek healthcare expertise in the adjacent medical district.

    Partnership and innovation opportunities abound for 22 WestEdge tenants—with unprecedented access to like-minded neighbors and colleagues in Charleston’s life sciences sector. Dr. David Cole, President of MUSC shared, “With MUSC’s $275 million of research and proprietary discoveries, 22 WestEdge will allow the University to collaborate with private industry to create new healthcare solutions, new companies and recruit existing global medical-related companies to Charleston.” Bob Quinn, Executive Director of the SCRA agreed, “SCRA’s leasing of the entire top floor of 22 WestEdge will allow us to create a world-class facility, including laboratories, which will serve as a catalyst for the attraction of leading life sciences companies and the creation of a Discovery District adjacent to MUSC.”  

    Charleston Mayor John Tecklenburg echoed, “It’s no secret that biomedical advances will be a key driver of our economy and society in the years ahead. With 156,000 square feet of office space dedicated to precisely the kind of research and enterprise that will help make those breakthroughs possible, 22 WestEdge is a welcome and important addition to our city’s medical district.”

    22 WestEdge office tenants will also benefit from the energy and vitality of the district. Recently completed, The Caroline has 237 apartments and 20,000 square feet of retail and restaurant space, and the topped-out 10 WestEdge will have 350 residential units, a Publix Super Market, Woodhouse Spa and additional retail and restaurant space, providing an abundance of shopping, eating and living options for all. 22 WestEdge’s own amenities include 15,000 square feet of cafes and fitness facilities, common conference and event facilities and a terrace wrapping the 7th floor with sweeping views of the Ashley River. Mack Reese, 22 WestEdge developer and partner, explains his reason for developing the project, “With its access to parking, numerous retail amenities and an urban density of residential opportunities for employees, the building will be a new and exciting option for existing Charleston businesses and those looking to relocate to the region.”

    Upon completion, WestEdge’s master-planned mixed-use district will encompass more than 3,000,000 square feet of space on 60 acres along the Ashley River adjacent to MUSC and the Medical District, and fronting on Brittlebank Park and the Joseph Riley Baseball Stadium. WestEdge is a public-private partnership created to advance economic development and expand the research capabilities of the Medical University of South Carolina and foster new companies and collaborative opportunities with private industry. It is an innovative redevelopment that is transforming the quality of life for Charleston’s west side.

    Key 22 WestEdge partners include Gateway Development (Developer) ELV Associates (Investor), BB&T (Lender), Trident Construction (General Contractor), Perkins & Will (Architect), Thomas and Hutton (Civil Engineer), and Lee & Associates (Marketing & Leasing).  

    For leasing inquiries and further detail on WestEdge development, please contact Mack Reese of Gateway Development (770-310-3414 ).  

  • Sam Patrick posted an article
    MUSC receives grant for expansion of telehealth program see more

    The Medical University of South Carolina (MUSC) palliative care program has received a $1,278,000 grant from The Duke Endowment to create a statewide, palliative care telehealth program.

    Providing end of life and comfort care to those in need, especially for the state’s most vulnerable and rural populations, is the primary aim of the new effort. Program leadership expects not only an improvement to accessibility for this kind of care, but also potential cost savings to individual patients and the system as a whole.  Click for full details.

  • Sam Patrick posted an article
    Moterum selected to present at prestigious medtech conference in Chicago, IL see more

    Southeastern medtech company develops mobility solutions for patients suffering from strokes, neural traumas; forum convenes investors seeking leading-edge advances in health and life sciences

     

     

    GREENVILLE, S.C. July 11, 2018Moterum Technologies Inc., a South Carolina-based mobility and gait rehabilitation development company, has been selected to present at the prestigious Cavendish BioHealth Impact Forum July 17-18, 2018 in Chicago, Illinois.  The Forum provides an environment for organizations and investors to further their strategic social impact investing, grant-giving, and philanthropy programs in support of health and life sciences advances. 

    Co-hosted by Cavendish Global, the Shirley Ryan AbilityLab, and MATTER, the Forum showcases presentations and panel discussions by leading research institutions, private-sector companies, nonprofit organizations, and foundations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.  Cavendish BioHealth Impact Forums are hosted by leading institutions around the United States and take place several times each year.

    Moterum Technologies is one of 10 featured organizations invited to present their solutions at the Chicago Conference.  An innovative medical technology development company, Moterum’s focus is designed to help resolve mobility and gait problems for patients suffering a neural trauma, such as a stroke.  Its lead product is a fully connected, smart device that teaches stroke patients how to re-learn walking in their own home.

    “We are honored to be selected to present at the 2018 Chicago Forum, and value the recognition it will provide of our innovative approach to helping stroke survivors walk independently and without a limp or asymmetry,” said David Huizenga, CEO of Moterum Technologies.  “Our device can be used at home and is fully connected and positioned for telehealth systems, making it a viable solution for developed and developing health systems alike.  We welcome the chance to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to improving the health and lives of people around the world.”

    The Cavendish community consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish BioHealth Impact Forum provides impact investors with a curated, peer-to-peer knowledge expansion and relationship building environment, and seeks to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing.  The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.

    “With the help of our expert team, Selection Committee and advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence,” said J. Michael Moffat, Chairman of Cavendish Global.  “The quality and originality of Moterum Technologies’ research and scientific insights in treating gait problems of stroke survivors positions them to make a major contribution to global health by helping stroke survivors retake an independent position in society.”

    For further information on Moterum Technologies, visit www.moterum.com.  


    About Moterum Technologies Inc.

    Moterum Technologies is an innovative medical technology development company that focuses on solving mobility and gait problems for patients suffering a neural trauma, such as a stroke.  Its lead product is a fully connected, smart device that teaches stroke patients to relearn how to walk in their own home.

  • Sam Patrick posted an article
    Hundreds of industry executives to convene Oct. 24-26 in Charleston, SC see more

    GREENVILLE, SC – Hundreds of industry executives, leaders in government and higher education, biotechnology and pharma executives, and industry supporters from across America will convene in Charleston, South Carolina for SCBIO 2017 – SCBIO’s Annual Conference -- October 24-26, 2017 at Charleston’s Gaillard Auditorium, organizers announced today.  Among the committed speakers and panelists are South Carolina Governor Henry McMaster, BIO Chief Executive Jim Greenwood, Nephron Pharmaceuticals CEO Lou Kennedy, MUSC President David Cole, and others.

    Early bird registration is now open for the conference, themed “Building the Business of Life SCiences in SC”, which draws attendees for intensive networking, innovation updates, opportunity discovery, partnership making and strategic discussion.  Registrants expected include top officials across a broad spectrum of life sciences industries including medical devices, bio manufacturing, drug discovery, pharmaceuticals, diagnostics and testing, digital health and health IT, bio ag  and more.  Interested attendees and sponsors can register at SCBIO 2017 Registration on Eventbrite for full details.  Advance registration is required, and space is limited.

    SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  SCBIO members are involved in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products.  The industry has an $11.4 billion economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the state’s burgeoning industry.

    SCBIO 2017 kicks off Tuesday evening with a Welcome Reception for conference registrants, speakers and sponsors on the rooftop terrace of the Grand Bohemian Hotel.  Wednesday will feature a full day of sessions beginning with a Welcome Breakfast, greeting by Charleston Mayor John Tecklenburg and an Industry CEO Panel.  A report on South Carolina’s exploding Life Sciences Industry featuring SCBIO CEO Sam Konduros and USC Darla Moore School of Business leader Dr. Joey Von Nessen will follow, as will a presentation by SC Deputy Secretary of Commerce Jennifer Fletcher.  SC Commerce is a Founding Partner of SCBIO and of the Conference.

    “The life sciences industry has become a major driver of South Carolina’s economy,” noted South Carolina Secretary of Commerce Bobby Hitt recently. “Already accounting for thousands of highly-skilled jobs in the Palmetto State, we know that this sector has tremendous growth potential, and we’re excited to be partnering with SCBIO to help life sciences continue to advance in South Carolina.”

    Wednesday’s program continues with a second CEO panel of leaders from South Carolina’s biotech industry delivering insight on organizational challenges and opportunities – including presenting sponsor Nephron Pharmaceutical CEO, Lou Kennedy, whose company has invested close to $400 million and recently relocated their global headquarters to the Palmetto State.

    ”South Carolina is a great home for the life sciences cluster, and Nephron Pharmaceuticals is happy to be part of it – and we thank SCBIO for its leadership,” stated Kennedy. The industry CEO panel will be followed by a luncheon featuring a keynote by Jim Greenwood, CEO of BIO.  Comments from South Carolina Governor Henry McMaster will follow Mr. Greenwood’s presentation.

    Highlights of Wednesday afternoon will include presentations on the transformational role of the state’s research institutions in our knowledge economy featuring MUSC David Cole and leaders from the state’s other research universities, followed by an interactive panel discussion with nationally respected venture capitalists on attracting additional capital to the state.  A reception for all registrants will follow.

    Thursday will cap SCBIO 2017 with a breakfast event designed to engage conference attendees directly in the strategic discussion, catalyzed by a presentation on “Building SC’s Life Sciences Industry” delivered by CEOs of scaling-up life sciences companies.  An interactive SWOT session on the needs of the industry in South Carolina will follow, and Thursday will culminate with self-selected interactive and facilitated sessions at which each attendee can interface with industry leaders, panelists, presenters and stakeholders of their choosing.

    As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – SCBIO members include scores of academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related organizations whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world.

    Committed sponsors of SCBIO 2017 include the South Carolina Department of Commerce; Nephron Pharmaceuticals; SCRA; Charleston Harbor Entrepreneur Center; KDS Commercial Real Estate; MUSC; the Charleston Regional Development Alliance; AVX; SiMT; Clemson University; University of South Carolina; the Upstate Alliance; VWR; SEMDA and many more.

    For additional information on SCBIO, visit www.SCBIO.org.  To register for SCBIO 2017, visit Event Brite and search “SCBIO 2017 annual conference”.

  • Sam Patrick posted an article
    Greenville, SC gains more accolades as a key cog in the state's emerging knowledge economy see more

    Greenville and South Carolina are in the national spotlight again as among America's emerging knowledge economy destinations.  SCBIO supporters Zylo Therapeutics, KIYATEC, VentureSouth and Chartspan are among the features companies in Bloomberg Businessweek's fabulous article.  Read on for the full story.

     

  • Sam Patrick posted an article
    Study to investigate potential impact to outcomes for several difficult-to-treat solid tumors see more

    3D-PREDICT Study to investigate potential impact to outcomes for several difficult-to-treat solid tumors

     

    GREENVILLE, SC. – June 20, 2018 – KIYATEC, Inc. today announced the enrollment of the first patients in a U.S. clinical study of its Ex Vivo 3D drug response assay (EV3D™) across several difficult-to-treat solid tumors. The 3D-PREDICT clinical study has been initiated at the Cancer Institute of Greenville Health System (GHS) with the goal of recruiting 640 patients across additional clinical sites to be added in the future.

    The 3D-PREDICT Study is a prospective, open-label, multi-institutional, non-interventional study to validate the EV3D assay for clinical use and to investigate the impact on outcomes for cancer patients with both newly diagnosed and recurrent epithelial ovarian cancer and recurrent high-grade gliomas, which include glioblastomas (GBM). Over the next year or so, the study will expand to include patients with newly diagnosed high-grade gliomas, high-grade rare tumors and triple negative breast cancer. The primary objectives of the study are to establish correlation between assay predicted drug response and patient clinical outcomes, and to measure the potential impact of the assay on therapeutic decision-making. The study is anticipated to continue through 2022. Details on the trial can be found on ClinicalTrials.gov

    The EV3D assay platform assesses a patient’s own cancer cells within a biologically relevant 3D culture microenvironment to provide individualized response prediction to specific therapeutic agents. In this study, the therapeutic agents predicted consist of available, guideline recommended drug options for each cancer type. 

    “As an institution, we’ve supported KIYATEC’s pilot clinical studies by providing over 450 samples of cancer tissues spanning the multiple tumor types they are testing and our clinical investigators are ready to take this important next step,” said Larry Gluck, MD, Medical Director of the GHS Cancer Institute. “Patients with recurrent ovarian cancer and recurrent GBM are among those with the most challenging prognosis at every cancer center around the country. The fact that KIYATEC is offering us a new tool in these very difficult to treat populations is a needle mover for these patients coming to Greenville for their treatment.”

    “Patients with these kinds of newly diagnosed and recurrent cancers simply do not have the luxury of time on their side. Their time, health and money spent on a treatment that is not working can have devastating consequences that we all want to avoid,” said Matthew Gevaert, CEO of KIYATEC. “The commencement of this clinical trial builds upon the success of our pilot studies and represents a significant milestone toward our goal of helping cancer patients receive the best treatment at the earliest possible time.”


    About KIYATEC, Inc.

    KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to chemotherapy drugs before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated process to use a cancer patient’s own live cells to accurately predict treatment response prior to beginning treatment.

     

    About Greenville Health System

    Greenville-based Greenville Health System (GHS) has partnered with Columbia-based Palmetto Health to form a not-for-profit health care delivery system serving 1.2 million patients annually across South Carolina. The new name and graphic identity are expected to be announced later this year. GHS offers patients an innovative network of clinical integration, expertise and technologies through its academic health system, eight medical campuses, tertiary medical center, research and education facilities, community hospitals, physician practices and numerous specialty services. GHS, by itself a 1,627-bed system, is home to 16 medical residency and fellowship programs, as well as partnership efforts such as the University of South Carolina School of Medicine Greenville and the soon-opening Clemson University Center for Nursing, Health Innovation and Research. Visit www.ghs.org for more information.

  • Sam Patrick posted an article
    South Carolina's life sciences industry is booming. Read on for details... see more

    From pharmaceuticals and medical devices to research and laboratory testing, the state's life sciences field is booming.  The Charleston and Lowcountry region is home to many established companies and start-ups making a mark on the biomedical and health industries.  Read on for the full story from Charleston Business Magazine's 2018 State of the Lowcountry Report.

  • Sam Patrick posted an article
    SCRA Collaboration Center Awards feature numerous life science organizations from across the state. see more

    South Carolina Research Authority’s SCRA-Academia Collaboration Team announces nearly $600,000 in feasibility grants for six projects. The awarded projects encourage collaboration between academic institutions and industry partners to advance commercially relevant research and establish the feasibility of the formation of Collaboration Centers. These Collaboration Centers will be founded for those areas demonstrating a critical mass of talent, infrastructure, financial resources, intellectual property and the prevalence of industry in South Carolina.

    “These Feasibility Grants are the first step in establishing Collaboration Centers, which will garner national recognition for South Carolina, create jobs, engage industry and have an overall positive impact on the state.” said Christine Dixon Thiesing, Director of Academic Programs. “SCRA is fostering the growth of collaboration across academic institutions and between academia and industry through the support of six innovation projects.”

    The Feasibility Grant Awards are the result of the efforts of the SACT, which was formed to deliver outcomes aligned with the Strategic Collaboration Agreement signed by SCRA and the presidents of the state’s research universities. The SACT is composed of representatives from the research universities, comprehensive teaching institutions, technical colleges, industry and SCRA. The SACT is currently evaluating the feasibility of establishing three Collaboration Centers – a Composites Industry Solutions Center, Medical Devices Collaboration Center, and Technology-Enabled Population Health Collaboration Center.

    The list of grant awardees is below:

    Composites Industry Solutions Center:
    Collaboration among Clemson University, Greenville Technical College and industry partners Kistler Instrument Corp., Keyence Corporation of America and Renishaw.

    Medical Devices Collaboration Center:
    Collaboration between the Medical University of South Carolina and Clemson University.

    Technology-Enabled Population Health Collaboration Center:
    Collaboration among the Medical University of South Carolina, Trident Technical College and industry partners Zeriscope, Inc. and Amanda Senior Care.

    Collaboration between Francis Marion University and a regional health organization as the industry partner.

    Collaboration among University of South Carolina – Upstate and industry partners ChartSpan Medical Technologies and a state agency.

    Collaboration among Clemson University, Florence-Darlington Technical College’s Southeastern Institute of Manufacturing and Technology and industry partner Greenville Health System.

  • Sam Patrick posted an article
    South Carolina life sciences gets another huge boost with BD's $150 million investment in Sumter see more

    Medical technology company creating 125 new jobs

     

    COLUMBIA, S.C. - BD (Becton, Dickinson and Company), a leading global medical technology company, today announced a $150 million investment in its existing Sumter County manufacturing facility. The company is projected to create an additional 125 new jobs over the next several years.

    Employing more than 65,000 associates worldwide, BD is one of the world's largest medical technology companies and supports health care providers in more than 190 countries. BD's Sumter County facility has been in operation since 1970, manufacturing blood collection devices that are critical to the health care industry. 

    Located at 1575 Airport Road in Sumter, S.C., BD's Sumter facility is actively hiring for the new positions, and interested applicants should visit www.bd.com/careers for more information.

    The Coordinating Council for Economic Development has approved job development credits related to this project, as well as a $600,000 Set Aside grant to assist with the costs of road work and site preparation.

     

    QUOTES

    "For nearly 50 years, BD's Sumter facility has consistently delivered superior quality products, vital for our customers and their patients, through a talented and engaged workforce. We would like to thank TheLINK economic development alliance, Sumter Economic Development, the City of Sumter, Sumter County and the S.C. Department of Commerce for their continued support of BD and our employees as we continue to invest in the facility. We look forward to the ongoing success of our BD Sumter manufacturing team as they continue to advance the world of health." -BD Executive Vice President of Global Operations and Chief Supply Chain Officer Jim Borzi

    "After opening in our state more than 40 years ago, we're thrilled that BD continues to grow and succeed here. This announcement once again demonstrates that South Carolina is a place where medical technology companies want to do business, and we welcome this new $150 million investment." -Gov. Henry McMaster

    "Not only does our state excel in advanced manufacturing, we're also increasingly a top choice for companies in the life sciences sector. BD has been a strong member of Team South Carolina for decades, and we congratulate them on their ongoing success." -Secretary of Commerce Bobby Hitt

    "BD has been a leading employer in this county since opening its doors in 1970. We are grateful for their continued investment in our community and our people." -Sumter County Council Chairman James McCain

    "We have long-enjoyed BD as a key component in the fabric of our industrial portfolio. This investment demonstrates their trust in our leadership, their commitment to the success of their business and their belief in our ability to regenerate the talent needed to produce the quality of goods for which BD is known." -Sumter Economic Development Chairman Greg Thompson


    FIVE FAST FACTS

    • BD is investing in its existing Sumter County manufacturing facility.
    • $150 million investment to create 125 new jobs.
    • Employing more than 65,000 associates worldwide, BD is one of the largest medical technology companies in the world and supports health care providers in more than 190 countries.
    • Located at 1575 Airport Road in Sumter, S.C., BD's facility manufactures blood collection devices for the health care industry.

    BD is actively hiring for the new positions, and interested applicants should visit www.bd.com/careers for more information.

     

    About BD

    BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit www.bd.com.

  • Sam Patrick posted an article
    ZEUS Industrial has acquired MWC Technologies, LLC see more

    ORANGEBURG, S.C., June 11, 2018 -- Zeus Industrial Products, Inc. (Zeus), a leading polymer extrusion manufacturer and material science innovator, today announced that it has acquired MWC Technologies, LLC (MWC). This adds to the capabilities that Zeus has been developing for the past five decades.

    MWC, a manufacturer of medical device components based in Chattanooga, TN, possesses innovative technologies that support Zeus' growth strategy. This acquisition will allow for the global commercialization of the many cutting-edge, solution-driven products in MWC's portfolio.

    Click to Tweet: @ZeusTubing acquires MWC Technologies: https://www.zeusinc.com/2018/06/11/zeus-acquires-mwc-technologies-llc/


    COMMENTS

    "Since I founded the company in 1966, Zeus has been focused on continuing to grow and innovate. This acquisition supports those goals. We are confident that our acquisition of MWC  will provide value to our customers today and into the future.." – Frank P. Tourville, Sr., Founder and Chairman of the Board, Zeus Industrial Products, Inc.

    "The acquisition of MWC  will expand our capabilities and product portfolio to address the rising demand for advanced precision extrusions. Our combined expertise will enhance our ability to better serve customers around the globe." – John Winarchick, CEO, Zeus Industrial Products, Inc.

    "We are excited to be joining the Zeus team!  Zeus's long term commitment to industry leading quality, customer service and innovation aligns well with MWC's culture.  Our combined technologies will enable new to the market solutions for our customers." – Eric Avans, Quality Manager, MWC Technologies

    RESOURCES

    Zeus Industrial Products: Learn more about the company and its products on the Zeus website; or call toll-free 1-800-526-3842 or +1-803-268-9500 outside the U.S.

    ABOUT ZEUS INDUSTRIAL PRODUCTS, INC.

    Zeus Industrial Products, Inc., is headquartered in Orangeburg, SC, USA. Its core business is the development and precision extrusion of advanced polymeric materials. The company employs over 1,500 people worldwide with manufacturing facilities in Aiken, Gaston and Orangeburg, South Carolina; Branchburg, New Jersey; and Letterkenny, Ireland. Zeus products and services serve companies in the medical, automotive, aerospace, fiber optics, energy and fluid management markets. For more information, visit www.zeusinc.com.

  • Sam Patrick posted an article
    John Osborne honored by Charleston Southern University see more

    CHARLESTON, S.C. – Charleston Southern University presented the Distinguished Service Award to John Osborne, a successful Charleston entrepreneur, at commencement ceremonies Saturday, May 5 at North Charleston Coliseum.

    Osborne is the executive administrator of Charleston Angel Partners, director of The Harbor Entrepreneur Center and managing partner of Good Growth Capital. In addition, he has a background in the financial services industry in commercial banking, private banking and wealth management with First Citizens Bank, Regions Bank, Bank of America and MassMutual.  Osborne also serves as a member of the Industry and Innovation Council of SCBIO, South Carolina's life sciences industry organization.  The Harbor Entrepreneur Center hosts SCBIO's Charleston office onsite.

    He received a bachelor of science in finance and economics from Charleston Southern in 2002 and played on the CSU men’s golf team for four years.

    “CSU provided a great foundation in my chosen major of finance and economics to build from as I continue to grow businesses which also support economic development efforts in our region,” said Osborne. “My involvement in startups stems from a combination of genuinely caring about seeing people pursue their passions and a recognition of the need for a more systematic way to connect people with resources to those who need them. It’s been a lifelong journey which is still evolving.”

    President Jairy C. Hunter Jr. said, “John always exhibits strong leadership skills and a willingness to help others. John is a superb example of a servant business leader. He is humble, intelligent and committed to helping entrepreneurs be successful in their business ventures. We are blessed that John chose to attend CSU. He was an excellent golfer and student. ”

    Osborne said, “To be recognized for service to the community, which is something I am passionate about, by CSU is a humbling honor for which I am grateful.”

    Osborne is a 2008 graduate of Leadership Charleston. He is currently serving on the West Ashley Revitalization Commission, the South Carolina Innovation Advisory Council, and is a founding member of the Start Up Champions Network. He has been recognized by Charleston Regional Business Journal as a 40 under 40; by Azalea Magazine as Visionary of the Year, and was named to Charlie Magazine’s 50 Most Progressive.

    He has been on the Board of Directors for Charleston Metro Chamber of Commerce, The Education Foundation, The Charleston International Film Festival and The Harbor Entrepreneur Center.

    Osborne and his wife, Allison, have two sons.

  • Sam Patrick posted an article
    U.S. bioscience industry has reached $2 trillion in annual economic impact while continuing to grow see more

    Boston, MA (June 5, 2018) –  A study released today at the BIO International Convention shows that the U.S. bioscience industry has reached $2 trillion in annual economic impact while maintaining accelerated venture capital investment and job growth numbers. Among U.S. technology sectors, the bioscience industry has held a leading position as an economic driver and job generator.

    The report, Investment, Innovation and Job Creation in a Growing U.S. Bioscience Industry 2018, finds U.S. bioscience firms directly employ 1.74 million people, a figure that includes more than 273,000 high-paying jobs created since 2001. The average annual wage for a U.S. bioscience worker reached $98,961 in 2016. These earnings are more than $45,000 greater, on average, than the overall U.S. private sector wage. The report further shows that since 2014, the bioscience industry has grown by 4.4 percent with four of its five major subsectors contributing to this overall job gain.

    For the first time, the biennial report includes a full assessment of the economic impact of the bioscience industry and finds its total economic impact on the U.S. economy, as measured by overall output, totaled $2 trillion in 2016. This impact is generated by the direct output of the bioscience industry combined with the indirect (supply chain) and induced (employee spending) impacts. The industry and its associated economic output support 8 million jobs throughout the entire U.S. economy through both indirect and induced effects.

    “This report highlights the enormous economic impact delivered by our industry. This strong performance is due to the vital and wide-ranging collaborations between industry partners, universities, and policymakers that provides a business climate that supports the development of innovative bioscience products and high paying jobs,” said Jim Greenwood, President and CEO of the Biotechnology Innovation Organization."

    The report also takes the pulse of the broader U.S. innovation ecosystem for bioscience companies and finds it advancing with positive results. The U.S. is experiencing strong gains in bioscience venture capital funding, growth in patents, a recent ramp-up in bioscience-related university R&D expenditures and increasing research funding from the National Institutes of Health (NIH).

    “The bioscience industry is vital to the U.S. not only as an innovation engine that is improving lives, but also as a major economic driver that is consistently generating high-quality jobs and significant economic output across the nation,” said Ryan Helwig, Principal and Project Director with TEConomy Partners.

    The state-by-state industry assessment is the eighth in a biennial series, developed in partnership by TEConomy and BIO, presenting data on national, state, and metropolitan area bioscience industry employment and recent trends.

    Additional highlights from the industry economic analysis include:

    • The industry is a major economic driver and is well distributed across U.S. states and cities:
      • 41 states experienced net job growth in the biosciences between 2014-2016
      • 38 states and Puerto Rico have an employment specialization in at least one bioscience subsector
      • 213 of 383 U.S. metropolitan areas have at least one bioscience specialization

    Highlights from the analysis of the innovation ecosystem for the bioscience industry include:

    • Strength in recent venture capital and patenting trends:
      • Venture capital investments have reached new highs. More than $66 billion in venture capital was invested in bioscience companies during the 2014 through 2017 period, including a new annual high in 2017 at $20 billion invested.
      • Innovation continues to drive the biosciences, since 2014 the U.S. has increased patent totals in bioscience-related technology classes by nearly 5 percent, or 1.6 percent per year, on average. 2017 had a total of nearly 27,000 patents awarded to U.S. inventors, another new high.
    • Growth for academic biosciences R&D in 2016
      • After several years of concerns raised about the declining and/or flat NIH research budgets and the subsequent effects on academic and other research, NIH funding is back on the rise. There have been budget increases sustained each of the last three years.
      • Across America’s colleges and universities, the pace of R&D spending in bioscience-related research areas has increased. Following a 1.5 percent decline in 2015, academic R&D expenditures in the biosciences increased 5.5 percent to $42 billion in 2016.

  • Sam Patrick posted an article
    South Carolina Named Top 3 in Best States for Business see more

    South Carolina has another opportunity to promote its economic development prowess thanks to a magazine’s business climate rankings.

    The Palmetto State tied for third with North Carolina in Chief Executive’s 2018 “Best and Worst States for Business.” Texas was No. 1, followed by Florida. Indiana was fifth.

    “A high ranking like this is a great tool that drives industrial prospects to consider South Carolina and our region for new investment and jobs,” says Will Williams, president and chief executive of the Economic Development Partnership, which serves Aiken, Edgefield, McCormick and Saluda counties.

    It was a slight improvement for the Palmetto State, which finished fourth in 2017. Economic development officials say there’s value in “best” lists.

    “We certainly use these types of rankings in our marketing to differentiate ourselves from other states and regions,” says John Lummus, president and chief executive of the Upstate SC Alliance, which serves a 10-county region. “I feel that these rankings are important not only because they shine a light on the positive, but also often show where improvements may need to be considered.”

    This latest ranking, which is based on a survey of CEOs, is in its 14th year. Publications devoted to business and/or economic development produce various types of state-by-state rankings throughout the year.

    “The Palmetto State consistently scores near the top due to a number of factors, such as low unionization rates, strong cooperation between government and business, low-cost utilities, established transportation and infrastructure, competitive wage rates, and availability of a talented workforce,” Lummus says.

    South Carolina ranked 10th overall in the Chief Executive rankings in 2015, fifth in 2014 and eighth in 2013.

    “This doesn’t just happen by accident,” says David Ginn, president and chief executive of the Charleston Regional Development Alliance. “The S.C. Department of Commerce is one of the best-performing economic development teams in the country.”

    Texas, Florida and North Carolina have been one-two-three for each of the past four years. Texas has been No. 1 all 14 years of the ranking’s existence.

    “The difference between the top five states is negligible, roughly within the statistical margin of error,” says John O’Toole, executive director of the Beaufort County Economic Development Corp.

    Meanwhile, California anchored the bottom of the list at No. 50 for the seventh consecutive year. The seven lowest-ranked states were all the same as in 2017.

    The magazine speculated that the reputations, leadership and governing philosophies in the top and bottom states don’t change much, while states in the middle of the rankings move up and down in response to those factors.

    “Our legislature has provided us tools to be competitive and our state and local permitting agencies understand the importance of keeping it simple,” Williams says. “Our collective economic development team has an enviable global reputation for delivering projects, both big and small, on time. And our focus on existing industry success demonstrates we take good care of you once you get here.”

    This year, the magazine noted that South Carolina was a right-to-work state and cited the South Carolina Innovation Plan, an initiative to support the advanced manufacturing, life sciences, biotech and computer software sectors.

    “In our targeted industries – aerospace, agribusiness, automotive, manufacturing and technology industries – we can compete with any state or nation,” O’Toole says.

    There were three subcategories used in the ranking: taxation/regulation, workforce quality and living environment. South Carolina ranked 10th, 14th and seventh in those three categories, respectively.

    Living environment is a selling point for O’Toole.

    “To punctuate our value proposition, at the end of the day you can be in Hilton Head, Beaufort, Bluffton or Port Royal,” he says. “What could be finer?”

    The Charleston area also makes many “best” lists related to quality of life and tourism.

    “National rankings make great headlines so we use them to grab attention and reinforce our strengths as a globally attractive location for business and talent,” Ginn says.

  • Sam Patrick posted an article
    KIYATEC growth supports upcoming programs to better predict patient response to oncology drugs see more

    GREENVILLE, SC. – May 29, 2018 – KIYATEC, Inc., a privately held company changing the future of cancer care by predicting patient response to oncology drugs prior to treatment, today announced an expansion of its leadership team with the appointment of two industry veterans. Charlene Knape has joined the company as Vice President of Clinical Affairs, and Timothy Decker as Vice President Commercial Operations.

    Mr. Decker, a twenty year industry leader with a proven track record of developing and commercializing oncology diagnostic services and pharmaceuticals, has assumed responsibility for pre-launch commercial strategic development along with tactical planning and execution to drive clinical product launches. Mr. Decker held roles of increasing responsibility in strategic and tactical marketing for a decade at G.D. Searle and Abbott Laboratories before joining Genomic Health, Inc.  Over an eight year span, he played a lead role as Director and Senior Director in the global launch, marketing, reimbursement and sales of Oncotype DX molecular diagnostic tests in breast, colon and prostate cancers. Mr. Decker subsequently served as Vice President of Marketing at Castle Biosciences, Inc., where he drove corporate and pipeline strategy, as well as in-line product strategy and revenue growth for its molecular diagnostic tests in melanoma. He joins the company from Mexico City-based Grupo Fármacos Especializados, where he served as Division Head, Oncology Diagnostics, responsible for developing reimbursement pathways and securing positive coverage decisions among public and private sector payers.

    With more than 25 years of experience working with diagnostic companies, Ms. Knape is responsible for leading the clinical development programs and clinical operations for KIYATEC’s pipeline for ovarian cancer, glioblastoma, rare tumors and triple negative breast cancer. She most recently served as Senior Director, Clinical Development for Inivata, a clinical cancer genomics company utilizing liquid biopsies for comprehensive genomic profiling of tumors. Prior to this, Ms. Knape served in Becton Dickinson’s Corporate Clinical Development group, responsible for global clinical quality and contracts. Ms. Knape spent five years with Micell Technologies as Senior Director of Clinical Affairs where she managed all global clinical activities for first-in-human and CE Marking studies for an implantable cardiovascular device from initiation through successful regulatory submission. As the company’s lead in clinical operations, Ms. Knape also built the team and initiated a 1,400-patient study in Europe and a 400-patient study in China. Previously, Ms. Knape served as Vice President, Clinical Affairs at EndoTex Interventional Systems, led the clinical functions for Avocet Medical and Somnus Medical Technologies and held clinical affairs positions in the Companion Diagnostics and Biorepository at LabCorp.

    “At this pivotal time in the company’s growth, we are thrilled to welcome Charlene and Tim to KIYATEC. These two newly created positions are critical as we expand our clinical programs in key therapeutic areas and further strengthen our plan for the broad adoption of our patient-specific response prediction tests,” said Dr. Matthew Gevaert, CEO of KIYATEC. “Their expertise and industry knowledge is unparalleled and they will be instrumental as KIYATEC continues toward its path of changing the future of cancer care by predicting patient response to chemotherapy before treatment begins. I’m so glad to have Tim and Charlene on our team as we move toward our goal of commercialization and helping patients receive optimal treatment at the earliest possible time.”

    KIYATEC will be attending the American Society of Clinical Oncology (ASCO) meeting being held June 1-5 in Chicago.

    About KIYATEC, Inc.

    KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to chemotherapy drugs before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated process to use a cancer patient’s own live cells to accurately predict treatment response prior to beginning treatment.

  • Sam Patrick posted an article
    Italian BioAg Firm Valagro launches $14 million production facility in Orangeburg County, SC see more

    COLUMBIA, S.C. – Valagro, a producer of biostimulants and fertilizers for the agriculture industry, is launching its new production operations in Orangeburg County. The company’s $14 million investment is projected to create 47 new, high-skilled jobs.

    Founded in 1980 and headquartered in the Abruzzo region of Italy, Valagro is a global leader in the world of biostimulants. The company specializes in the production and marketing of specialty nutrients for use in agricultural production and other industrial applications. Valagro operates through its 12 subsidiaries and owns a commercial network covering more than 80 countries worldwide. Providing innovative and effective solutions for plant nutrition and care, the company’s mission is to increase the quantity and quality of plants and harvested crops while enhancing productivity and reducing environmental impact.

    Located at 397 Millennium Drive in Orangeburg, S.C., Valagro’s new, 65,000-square-foot Orangeburg County facility is expected to come online in the third quarter of 2019. Construction is expected to begin in the fourth quarter of 2018.

    For more information on Valagro, visit the company’s website at https://www.valagro.com/en.

    The Coordinating Council for Economic Development has approved job development credits, as well as a $100,000 Rural Infrastructure Fund grant to Orangeburg County to assist with the costs of building construction.
     

    QUOTES

    “The construction of this U.S. production facility greatly supports our ability to better serve some of the most strategically-important markets, such as the U.S., Canada and Mexico. This means fully implementing Valagro’s principle of putting the customer in the center; the new facility will allow us to improve our ability to meet customers’ needs by providing them with a wide range of sustainable and effective nutritional solutions.” –Valagro CEO Giuseppe Natale

    “Today, we celebrate yet another international firm choosing to do business in South Carolina, a further testament to our business-friendly climate and well-trained workforce. I congratulate Valagro and Orangeburg County on this terrific new partnership and look forward to watching it thrive for years to come.” –Gov. Henry McMaster

    “When a new business comes to South Carolina, it speaks volumes not only about our business climate, but also about our workforce. I am excited to see what the future has in store for Valagro and their new home in Orangeburg County.” –Secretary of Commerce Bobby Hitt

    “We welcome Valagro to South Carolina and to Orangeburg County. Valagro is joining one of the state’s top industries, and we’re eager to share our agribusiness-friendly climate with this international company as it builds its new U.S. production facility.” –S.C. Agriculture Commissioner Hugh Weathers

    “South Carolina Ports Authority welcomes Valagro to our state and looks forward to serving its import needs. The Port plays an important role in the international supply chains of manufacturers across our state, and we look forward to supporting their addition to our growing economy.” –S.C. Ports Authority President and CEO Jim Newsome

    “Orangeburg County welcomes Valagro to our community. We are grateful they have chosen Orangeburg County as your first manufacturing facility in the U.S. It is a testament to our skilled workforce, location and pro-business environment. We thank Valagro for their investment in our county and our citizens.” –Orangeburg County Council Chairman Johnnie Wright Sr.

    “I join with the Orangeburg City Council in welcoming Valagro, a leader in the production and marketing of biostimulants and specialty nutrients. Their commitment is a positive reflection of our workforce and will provide quality careers for our citizens. By creating these jobs, 47 families will benefit, and our community will continue to prosper. We look forward to working with the company and celebrating its success.” –Orangeburg Mayor Michael C. Butler

    “We’re delighted that Valagro has selected Orangeburg County for its next facility. The company’s expansion into Orangeburg County is a boon for the local economy and workforce and further confirms South Carolina’s position as a strong competitor in attracting international companies looking to grow their business in the U.S.” –Central S.C. Alliance Chairman Mike Brenan